Case Reports: Lung Injuries from the Vaccine

Over the past few months, we've been providing you with case reports and details that are basically undeniable about specific injuries documented from the vaccines. These case studies are used and produced by professional medical researchers, who are documenting specific autopsies, biopsies, and other elements that help us understand how the Covid vaccines have potentially and probably injured many, many people. Here is a list of case studies explaining in layman's English the findings of specific cases:

Study 1: Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer-BioNTech)

This case study involves a 66-year-old man with squamous cell carcinoma who had been receiving chemoradiation therapy after stereotactic radiotherapy for brain metastases. The patient was given atezolizumab as a second-line therapy, which led to him becoming progression- and recurrence-free. However, four days after his second dose of the Pfizer-BioNTech COVID-19 vaccine, the patient developed persistent hemoptysis (coughing up blood). Despite having no thrombocytopenia or coagulation abnormalities, bronchoscopy revealed active bleeding from the left lingual tracheal branch. The patient was admitted to the intensive care unit due to increased bleeding and underwent left bronchial artery embolization. Hemostasis was achieved after the procedure, and the patient was discharged seven days after the onset of hemoptysis. The study suggests that the hemoptysis was potentially induced by the vaccination. Link to the study

Study 2: Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report

This case study involves a 55-year-old man with stage IV non-small cell lung cancer who was on ipilimumab and nivolumab maintenance therapy. He experienced minor side effects such as injection site pain and slight fever after the first and second COVID-19 vaccinations (BNT162b2). However, the day after his third COVID-19 vaccination (mRNA-1273), he developed a high fever and lost consciousness. Brain MRI showed parietal meningitis, and cytokine levels were elevated. Grade 2 liver and renal dysfunction were also observed. After ruling out infection and a negative PCR test for SARS-CoV-2, a diagnosis of Cytokine Release Syndrome (CRS) due to COVID-19 vaccination was made. His symptoms improved dramatically after steroid therapy. The study concludes that there was a close association between the time course after vaccination and clinical symptoms of high fever and lost consciousness, suggesting the possibility of vaccine-induced adverse effects such as CRS. Link to the study

Study 3: A case of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung diseases developed after administration of COVID-19 vaccine and subsequent pneumococcal vaccine

This case study discusses a 75-year-old Japanese man who developed anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung diseases (anti-MDA5-positive DM-RPILD) after receiving the Pfizer COVID-19 vaccine and a pneumococcal vaccine. The patient had a mild COVID-19 infection and received the third dose of the Pfizer COVID-19 vaccine four weeks later. Eleven weeks after vaccination, he received the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for the first time. The day after receiving the PPSV23, he developed fever, malaise, and anorexia, followed by a rash a week later and shortness of breath two weeks later. Despite intensive treatment, the patient's condition worsened, and he died on the 10th day of hospitalization. The study suggests that the sequence of COVID-19 infection, COVID-19 vaccination, and PPSV23 administration may have contributed to the development of anti-MDA5-positive DM-RPILD. Link to the study

Study 4: A RAPIDLY PROGRESSIVE AND RARE ILLNESS: AUTOANTIBODIES AGAINST MELANOMA DIFFERENTIATION-ASSOCIATED PROTEIN 5 (ANTI-MDA5): AMYOPATHIC DERMATOMYOSITIS WITH PROGRESSIVE INTERSTITIAL LUNG DISEASE THAT DEVELOPED AFTER COVID-19 VACCINE

This case study presents a 58-year-old man who was admitted to the Intensive Care Unit due to respiratory failure and shock. His illness started four days after receiving a novel mRNA COVID-19 Vaccine. He developed symptoms such as bilateral extremities edema, oral sores, worsening fatigue, and dyspnea on exertion. Despite outpatient treatment for pneumonia and prednisone for vaccine reaction, his condition worsened. He was admitted to the hospital with fever, progressive dyspnea, and fatigue. A chest CT revealed diffuse and sub-pleural ground-glass opacities. A skin biopsy confirmed the diagnosis of amyopathic dermatomyositis with progressive interstitial lung disease. His ICU course was complicated by pneumomediastinum, pneumothorax, and pericardial effusion. The study concludes that while there was insufficient evidence to definitively demonstrate a direct correlation between the vaccination and the patient's illness, conditions that lead to a cytokine storm with subsequent development of ARDS or multi-organ dysfunction are associated with progressive clinical deterioration and a high risk of death. Link to the study

Study 5: Ultrastructural findings of lung injury due to Vaccine-induced Immune Thrombotic Thrombo- cytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study

This study investigates the lung injury caused by Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT), a rare syndrome that occurs after the ChAdOx1 nCoV-19 vaccine immunization. The study reports the ultrastructural findings of lung injury in a patient who died from VITT. The patient had severe thrombocytopenia, cerebral venous sinus thrombosis, and multiple organ failure. The lung tissue was examined using scanning electron microscopy, which revealed widespread capillary congestion with numerous platelet aggregates, fibrin thrombi, and damaged endothelial cells. The study concludes that these findings provide new insights into the pathogenesis of VITT and the severe lung injury associated with it. Link to the study

Study 6: Severe autoimmune haemolytic anaemia following SARS-CoV-2 vaccination in patients with treatment naïve B-cell neoplasms: a case series

This case series discusses severe autoimmune hemolytic anemia (AIHA) in patients with treatment-naive B-cell neoplasms following SARS-CoV-2 vaccination. AIHA is a rare condition where the immune system destroys red blood cells faster than the body can produce them, leading to anemia. The study presents cases of patients who developed severe AIHA after receiving the COVID-19 vaccine. Although the abstract is not available, the title suggests that the study explores the potential link between COVID-19 vaccination and the onset of AIHA in patients with B-cell neoplasms, a type of cancer that forms in B cells (a type of white blood cell). The study likely discusses the clinical presentations, management, and outcomes of these patients. Link to the study

Study 7: Bilateral Axillary Lymphadenopathy After COVID-19 Vaccine Presenting for Lymph Node Surgical Biopsy: A Case Report

This case report discusses an individual who experienced non-self-remitting bilateral axillary lymphadenopathy (swelling of the lymph nodes in the armpit area) after receiving two doses of the Pfizer-BioNTech COVID-19 mRNA vaccine. This side effect was not seen during the clinical trial phase of the vaccine creation, leading to the individual undergoing a full medical workup, including ultrasound, computed tomography (CT) scans, blood work, and ultimately needing surgical intervention to have the axillary lymphadenopathy excised. The report aims to shed light on this new, undocumented adverse reaction that should be included in physicians' differential diagnoses in individuals after receiving the COVID-19 vaccine, particularly the Pfizer-BioNTech COVID-19 mRNA vaccination. This information could help future patients avoid unnecessary extensive medical workups, surgical procedures, being exposed to anesthesia, or having the burden of additional unwarranted healthcare costs. Link to the study

Study 8: Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination

This editorial discusses vaccine-induced interstitial lung disease (ILD), a rare reaction to COVID-19 vaccination. ILD involves inflammation and scarring of the lung tissue, leading to a range of symptoms such as shortness of breath and cough. The editorial is a comment on a case study titled "COVID-19 vaccine-related interstitial lung disease: a case study," which reported a case of ILD after COVID-19 vaccination. Link to the study

Study 9: A case of severe interstitial lung disease after COVID-19 vaccination

This case report discusses severe interstitial lung disease (ILD) that developed in a patient after receiving the COVID-19 vaccination. ILD involves inflammation and scarring of the lung tissue, leading to a range of symptoms such as shortness of breath and cough. The details of the case are not available in the abstract, but the title suggests that the study explores a severe case of ILD that occurred post-vaccination. The study likely discusses the clinical presentation, management, and outcomes of this patient, and it may explore the potential link between COVID-19 vaccination and the onset of severe ILD. Link to the study

Study 10: A case of adenoviral covid-19 vector vaccine possibly linked to severe but reversible interstitial lung injury post-vaccination

This case study reports a 55-year-old male who presented with severe respiratory failure and myocardial infarction eighteen days after receiving the first shot of the adenoviral AZD1222 vector vaccine. The patient responded impressively to high dose steroids, and a repeat chest CT nine days after the first one showed a remarkable resolution of the bilateral ground glass opacities. The patient was discharged without supplemental oxygen or steroids, and on one month follow-up, no residual pulmonary dysfunction was noticed. The study concludes that vaccine-induced interstitial lung disease (ILD) might be a rare adverse event post-COVID-19 vaccination. Early suspicion and recognition of post-vaccination ILD, followed by prompt implementation of steroid treatment, can significantly reverse the lung lesions without progression to fibrosis. Link to the study

Study 11: Diabetic ketoacidosis shortly after COVID-19 vaccination in a non-small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report

This case report describes a 65-year-old woman with non-small-cell lung cancer who developed diabetic ketoacidosis (DKA) shortly after receiving the COVID-19 vaccine. The patient was under a combination treatment of programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors and had no history of diabetes mellitus. The onset of DKA occurred a few days after the second shot of the COVID-19 vaccine. The authors speculate that the immune-related adverse event and the immunogenicity of the vaccination might have synergistically induced DKA in this patient. Link to the study

Study 12: Interstitial lung disease after receiving the mRNA-based COVID-19 vaccine tozinameran

This case report discusses a 71-year-old Japanese woman who developed interstitial lung disease (ILD) after receiving an mRNA-based COVID-19 vaccine. ILD involves inflammation and scarring of the lung tissue, leading to a range of symptoms such as shortness of breath and cough. The patient developed symptoms of dyspnea or hypoxia within 1-3 days after vaccination. The authors suggest that further studies are needed to understand the mechanisms and risk factors of rare adverse reactions such as ILD after COVID-19 mRNA vaccination. Link to the study

Study 13: COVID-19 vaccine-related interstitial lung disease: a case study

This case study discusses a patient who developed interstitial lung disease (ILD) after receiving the COVID-19 vaccine. ILD involves inflammation and scarring of the lung tissue, leading to a range of symptoms such as shortness of breath and cough. The details of the case are not available in the abstract, but the title suggests that the study explores a case of ILD that occurred post-vaccination. The study likely discusses the clinical presentation, management, and outcomes of this patient, and it may explore the potential link between COVID-19 vaccination and the onset of ILD. Link to the study

Study 14: COVID-19 mRNA vaccine-related interstitial lung disease: Two case reports and literature review

This study presents two cases of interstitial lung disease (ILD) that developed after receiving the Pfizer-BioNTech mRNA COVID-19 vaccine. The patients, a 67-year-old man and a 70-year-old man, both had underlying ILD and presented with fever and respiratory symptoms a few days after vaccination. One case was diagnosed with lymphocytic alveolitis through bronchoalveolar lavage fluid and transbronchial lung cryobiopsy. Both patients were successfully treated with corticosteroids and attended outpatient clinics thereafter. The study emphasizes the need for further research to understand rare adverse reactions to COVID-19 vaccines. Link to the study

Study 15: Severe acute interstitial lung disease after BNT162b2 mRNA COVID-19 vaccination in a patient post HLA-haploidentical hematopoietic stem cell transplantation

This case report discusses a patient who developed severe acute interstitial lung disease after receiving the BNT162b2 mRNA COVID-19 vaccine. The patient had previously undergone a HLA-haploidentical hematopoietic stem cell transplantation. The details of the case are not available in the abstract, but the title suggests that the study explores a severe case of interstitial lung disease that occurred post-vaccination in a patient with a specific medical history. The study likely discusses the clinical presentation, management, and outcomes of this patient, and it may explore the potential link between COVID-19 vaccination and the onset of severe acute interstitial lung disease in this context Link to the study

Study 16: COVID-19 vaccine induced interstitial lung disease

This case report discusses a 60-year-old man who experienced shortness of breath four days after receiving the second dose of the COVID-19 vaccine. The patient's imaging revealed extensive ground-glass opacification, a common sign of interstitial lung disease. Blood tests showed elevated KL-6 levels, and bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and a decreased CD4/CD8 ratio. These findings led to a diagnosis of drug-induced interstitial lung disease (DIILD), which, to the authors' knowledge, had not been reported in previous literature in relation to the COVID-19 vaccine. The patient's symptoms were relieved after treatment with glucocorticoids. The study highlights that while extremely rare, the COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial for improving patient outcomes. Link to the study

Study 17: A case of interstitial lung disease following Oxford-AstraZeneca COVID-19 vaccination

This case study discusses a patient who developed interstitial lung disease (ILD) after receiving the Oxford-AstraZeneca COVID-19 vaccine. ILD involves inflammation and scarring of the lung tissue, leading to a range of symptoms such as shortness of breath and cough. The details of the case are not available in the abstract, but the title suggests that the study explores a case of ILD that occurred post-vaccination. The study likely discusses the clinical presentation, management, and outcomes of this patient, and it may explore the potential link between COVID-19 vaccination and the onset of ILD.Link to the study

Study 18: A case of adenoviral covid-19 vector vaccine possibly linked to severe but reversible interstitial lung injury post-vaccination This case report discusses a patient who developed severe but reversible interstitial lung injury after receiving an adenoviral COVID-19 vector vaccine. The patient was treated and recovered, suggesting that while severe, the lung injury was not permanent. The study highlights the need for further research to understand the potential link between COVID-19 vaccines and lung injury. Link to the study

Study 19: Diabetic ketoacidosis shortly after COVID-19 vaccination in a non-small-cell lung cancer patient receiving combination of PD-1 and CTLA-4 inhibitors: A case report This case report discusses a patient with non-small-cell lung cancer who developed diabetic ketoacidosis shortly after receiving the COVID-19 vaccine. The patient was also receiving a combination of PD-1 and CTLA-4 inhibitors, which are types of immunotherapy used to treat cancer. The study suggests that the vaccine may have triggered the diabetic ketoacidosis, but more research is needed to confirm this.
Link to the study

Study 20: Interstitial lung disease after receiving the mRNA-based COVID-19 vaccine tozinameran This case report discusses a patient who developed interstitial lung disease after receiving the mRNA-based COVID-19 vaccine tozinameran. The details of the case are not available in the abstract, but the title suggests that the study explores a case of interstitial lung disease that occurred post-vaccination.
Link to the study